We selected a number of in vitro and in vivo preclinical CRC RAS/BRAF wt models to mimic the clinical setting in which EGFR blockade is used and tested our hypotheses by treating them with VitC and cetuximab alone or in combination. Here, BRAF is linked to colorectal carcinoma.